← Back to headlines
Teva Pharmaceuticals to Acquire BioXcel Assets for Up to $125 Million
Israeli drugmaker Teva Pharmaceuticals has announced plans to purchase select assets from BioXcel Therapeutics in a deal valued at up to $125 million, expanding its portfolio in neuroscience and rare disease treatments.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
